From: The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma
Variable | Overall survival (OS) | Disease-free survival (DFS) | ||
---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
T stage (T1 + T2 vs. T3 + T4) | 1.73 (1.09–4.01) | 0.221 | 1.43 (0.35–5.52) | 0.136 |
N stage (N0 vs. N1 + N2) | 5.95 (3.62–9.22) | <0.001* | 3.67 (1.59–7.44) | 0.018* |
M stage (N0 vs. M1) | 4.04 (1.79–12.55) | 0.014* | 5.43 (1.69–20.04) | <0.001* |
Differentiation (Well vs. Moderate + Poor) | 2.99 (1.30–6.88) | 0.025* | 2.21 (1.05–9.62) | 0.029* |
NLRP3 (Low vs. High) | 3.81 (0.36–8.08) | 0.014* | 1.88 (0.33–4.12) | 0.194 |
NLRP3/Ki-67 (Both low vs. Both high) | 7.79 (3.48–13.27) | <0.001* | 12.27 (4.25–19.45) | <0.001* |